![Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors]()
Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumorsMukai, Hirofumi; Kato, Ken; Esaki, Taito; Ohsumi, Shouzou; Hozomi, Yasuo; Matsubara, Nobuaki; Hamaguchi, Tetsuya; Matsumura, Yasuhiro; Goda, Rika; Hirai, Takayuki; Nambu, Yoshihiro · Investigational New Drugs · 2016